✦ LIBER ✦

The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

✍ Scribed by Paolo Barone; Angelo Antonini; Carlo Colosimo; Roberto Marconi; Letterio Morgante; Tania P. Avarello; Eugenio Bottacchi; Antonino Cannas; Gabriella Ceravolo; Roberto Ceravolo; Giulio Cicarelli; Roberto M. Gaglio; Rosa M. Giglia; Francesco Iemolo; Michela Manfredi; Giuseppe Meco; Alessandra Nicoletti; Massimo Pederzoli; Alfredo Petrone; Antonio Pisani; Francesco E. Pontieri; Rocco Quatrale; Silvia Ramat; Rosanna Scala; Giuseppe Volpe; Salvatore Zappulla; Anna Rita Bentivoglio; Fabrizio Stocchi; Giorgio Trianni; Paolo Del Dotto

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 178 KB
Volume: 24
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22643

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intrajejunal levodopa infusion in Parkin

Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life

✍ Holger Honig; Angelo Antonini; Pablo Martinez-Martin; Ian Forgacs; Guy C. Faye; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

## Abstract Switching from oral medications to continuous infusion of levodopa/carbidopa gel reduces motor complications in advanced Parkinson's disease (PD), but effects on nonmotor symptoms (NMSs) are unknown. In this prospective open‐label observational study, we report the effects of intrajejun

The impact of treatment of depression on

The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease

✍ Matthew Menza; Roseanne DeFronzo Dobkin; Humberto Marin; Margery H. Mark; Michae 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 318 KB 👁 1 views

## Abstract Parkinson's disease (PD) is a common neurodegenerative disease affecting up to one million individuals in the United States. Depression is found in 40 to 50% of these patients and is associated with a variety of poor outcomes for both patients and their families. Despite this, there are

A population-based study of the impact o

A population-based study of the impact of specific symptoms on quality of life in women with breast cancer 1 year after diagnosis

✍ Volker Arndt; Christa Stegmaier; Hartwig Ziegler; Hermann Brenner 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 2 views

Progression and prognostic factors of mo

Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease

✍ Bart Post; Dino Muslimovic; Nan van Geloven; Johannes D. Speelman; Ben Schmand; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

## Abstract ## Objective: To determine progression and prognostic factors of progression rate of motor impairment, disability, and quality of life (QoL) in patients with newly diagnosed Parkinson's disease. ## Methods: A group of 126 patients with newly diagnosed PD recruited from outpatient cli

Impact of oral cyclophosphamide on healt

Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study

✍ Dinesh Khanna; Xiaohong Yan; Donald P. Tashkin; Daniel E. Furst; Robert Elashoff 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

## Abstract ## Objective To assess the impact of cyclophosphamide (CYC) on the health‐related quality of life (HRQOL) of patients with scleroderma after 12 months of treatment. ## Methods One hundred fifty‐eight subjects participated in the Scleroderma Lung Study, with 79 each randomized to CYC

The effects of rasagiline on cognitive d

The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study

✍ Hasmet A. Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the ef